世界卫生组织欧洲区域2005—2019年风疹消除进展
该报告描述了世界卫生组织欧洲区域2005—2019年风疹和先天性风疹综合征(CRS)的消除进展。CRS病例从2005年16例降至2019年8例(下降50%)。为实现并维持消除目标,需加强免疫规划、为易感成人提供补充接种、维持高质量监测并做好暴发应对准备。
要点
- 2019年仅31个(58%)国家RCV1覆盖率达到≥95%,区域消除目标尚未全面实现。
- CRS病例从2005年16例降至2019年8例,下降50%。
核心结论
- 欧洲区域风疹发病率在2005—2019年下降超过99%,但2019年仅58%国家RCV1覆盖率达≥95%,消除目标仍需加强措施。
研究设计与样本
- 基于世界卫生组织欧洲区域2005—2019年风疹和CRS监测及免疫覆盖数据的进展报告。
主要发现
- 2005—2019年区域RCV1估算覆盖率为93%—95%,2019年31个(58%)国家达到≥95%。
- CRS病例从2005年16例降至2019年8例,下降50%。
关键数值与推荐
- WHO推荐的欧洲区域麻疹和风疹消除策略包括:通过常规免疫服务实现并维持2剂含麻疹和风疹疫苗(MRCV)≥95%覆盖率。
- 为易感人群提供麻疹和风疹疫苗接种机会,包括补充免疫活动(SIA)。
- 加强监测,通过病例调查和实验室结果确认疑似病例和暴发。
- 改善证据的可及性和使用,向卫生专业人员和公众清晰传达接种疫苗预防这些疾病的获益和风险。
临床怎么用
- 确保每个国家的每个地区RCV覆盖率≥95%,为易感成人提供补充风疹疫苗接种。
- 维持高质量监测以快速发现和确认病例,并确保有效的暴发准备和应对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2005, the Regional Committee of the World Health Organization (WHO) European Region (EUR) passed a resolution calling for the regional elimination of measles, rubella, and congenital rubella syndrome (CRS) (1). In 2010, all 53 countries in EUR* reaffirmed their commitment to eliminating measles, rubella, and CRS (2); this goal was included in the European Vaccine Action Plan 2015-2020 (3,4). Rubella, which typically manifests as a mild febrile rash illness, is the leading vaccine-preventable cause of birth defects. Rubella infection during pregnancy can result in miscarriage, fetal death, or a constellation of malformations known as CRS, which usually includes one or more visual, auditory, or cardiac defects (5). The WHO-recommended measles and rubella elimination strategies in EUR include 1) achieving and maintaining ≥95% coverage with 2 doses of measles- and rubella-containing vaccine (MRCV) through routine immunization services; 2) providing measles and rubella vaccination opportunities, including supplementary immunization activities (SIAs), to populations susceptible to measles or rubella; 3) strengthening surveillance by conducting case investigations and confirming suspected cases and outbreaks with laboratory results; and 4) improving the availability and use of evidence to clearly communicate the benefits and risks of preventing these diseases through vaccination to health professionals and the public (6). This report updates a previous report and describes progress toward rubella and CRS elimination in EUR during 2005-2019 (7). In 2000, estimated coverage with the first dose of a rubella-containing vaccine (RCV1) in EUR was 60%, and 621,039 rubella cases were reported (incidence = 716.9 per 1 million population). During 2005-2019, estimated regional coverage with RCV1 was 93%-95%, and in 2019, 31 (58%) countries achieved ≥95% coverage with the RCV1. During 2005-2019, approximately 38 million persons received an RCV during SIAs in 20 (37%) countries. Rubella incidence declined by >99%, from 234.9 cases per 1 million population (206,359 cases) in 2005 to 0.67 cases per 1 million population (620 cases) by 2019. CRS cases declined by 50%, from 16 cases in 2005 to eight cases in 2019. For rubella and CRS elimination in EUR to be achieved and maintained, measures are needed to strengthen immunization programs by ensuring high coverage with an RCV in every district of each country, offering supplementary rubella vaccination to susceptible adults, maintaining high-quality surveillance for rapid case detection and confirmation, and ensuring effective outbreak preparedness and response.
引用
- O'Connor P, Jankovic D, Zimmerman L, et al. Progress Toward Rubella Elimination - World Health Organization European Region, 2005-2019. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34111057. doi:10.15585/mmwr.mm7023a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。